Category Archives: Biotech Empire

Neurocore Offers “Ground-Breaking Therapy” To Those Who Suffer From ADHD

Attention Deficit Hyperactivity Disorder (ADHD) is a disorder that interferes with a person’s ability to pay attention and control impulsive behaviors. Another symptom commonly related to this disorder is hyperactivity. Although it is common to have some degree of inattention and unfocused motor activity, people who suffer from ADHD typically experience these situations more severely and with more frequent occurrences.


Neurocore’s “Ground-Breaking Therapy”

In an article dated January 21st of 2019, it talks about a “ground-breaking therapy” in treating ADHD. The article begins in saying that the disorder affects children, teens, and adults. To quote, “roughly 4% of U.S. adults suffer from ADHD.” The article also includes a general account of American women who also suffer from the disorder.

The article then talks about treatment options for ADHD and how it “continues to grow.” Outside prescribed medication and conventional therapy, ADHD can now be treated using neurofeedback. The information obtained from neurofeedback can then be used to “create a brain training program” to treat patients suffering from ADHD. The article describes neurotherapy as a type of therapy that “uses real-time electroencephalography (EEG)”. By way of “brainwave sensing electrodes placed on the scalp”, the information extracted by the EEG allows the patient, neuropsychologist, and clinicians to “observe” the brain and, from it, gather key data. This data is then analyzed and is used to customize a treatment or therapy for the patient. The article then moves forward in providing “16 facts” about the new therapy and the company who offers it.



Founded in 2004, Neurocore based out of Boca Raton, FL offers its services at their brain performance centers in Michigan and Florida. Headquartered in Michigan, Neurocore has brain performance centers located in Grand Rapids, Livonia, West Bloomfield, Grandville, and Sterling Heights. Outside of Michigan, Neurocore also operates in Boca Raton, Florida.

The company offers treatment and therapy to those who suffer from ADHD, anxiety, and stress to just mention a few. They also offer several programs to treat memory loss. Athletes have also been known to use their services to boost mental strength and stamina.

Dr. Tim Royer is the Founder of Neurocore and Rick Kuiper serves as President. Mark Murrison serves as the company’s Chief Executive Officer, and Dr. Elyse Kemmerer White is the Chief Science Officer.

Next, the article then discusses the details surrounding neurofeedback and neurotherapy. Additionally, the article also includes a detailed discussion about ADHD.

If you would like to view the full article, please click here.

How Clay Siegall Built A Biotech Empire

In 1988, Dr.Clay Siegall co-founded biotech company Seattle Genetics, where he is currently the President, Chairman of the Board and Chief Executive Officer. A renowned scientist trained in research of cancer therapies, he built the company based on a foundation of strong research and drug development. The team has the same passion that the company founder has for helping patients and scientific innovation. The company has a roster of over 900 employees and has a market value of almost $10 billion. Because of this, Seattle Genetics is already ranked as Washington’s largest biotech company. By adding 200 more people to its staff this year and investing heavily in marketing and research, Dr. Siegall hopes that his company can make the leap from biotech research to big pharma.

Clay Siegall’s Educational and Career Achievements

Clay Siegall received his Ph.D. in genetics from the George Washington University and his Bachelor’s degree in Zoology from the University of Maryland. Before he founded Seattle Genetics, he worked at the National Institutes of Health’s Cancer Institute from 1988 to 1991 and later the Bristol-Myers Squibb Pharmaceutical Research Institute between 1991 and 1997. He sits on the Boards of Alder BioPharmaceuticals, Washington Roundtable, and Ultragenyx Pharmaceutical. Clay has also received numerous awards, including the Pacific Northwest Ernst & Young Entrepreneur of the Year for 2012 and the University of Maryland Alumnus of the Year in Computers, Math and Natural Sciences in 2013.

Achievements with Seattle Genetics

Dr. Clay Siegall has guided Seattle Genetics to its current position as an industry leader by developing several antibody drug conjugates (ADCs) while helping to secure FDA approval in 2011 of the company’s first ADC product known as ADCETRIS®. ADCETRIS® has grown into a globally recognized brand, available in more than 65 countries around the world. Besides, the company is also developing proprietary ADCs that will be used in the treatment of cancer. Dr. Siegall has led Seattle Genetics to enter into several strategic licenses with major pharmaceutical companies for the ADC technology it develops, in the process managing to generate more than $350 million in revenues. He has also been at the forefront of the company’s capital-raising activities, helping it to secure funding amounting to more than $1.2 billion, via a combination of public and private funding. That includes the company’s initial public offering in 2001.